Consensus on clinical management of tumor-induced osteomalacia

Title: Consensus on clinical management of tumor-induced osteomalacia
Edition: Original
Classification: Experts consensus
Field: Diagnosis and Management
Countries and regions: China
Guidelines users: Health practitioners, endocrinologists, orthopedists, rheumatology immunologists
Evidence classification method:
Development unit: Chinese Society of Osteoporosis and Bone Mineral Research, Chinese Society of Endocrinology
Registration time: 2021-01-29
Registration number: IPGRP-2021CN023
Purpose of the guideline: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by excessive fibroblast growth factor 23 (FGF23) production by a tumor which often arises from a mesenchymal origin. Most clinical symptoms of TIO are the consequences of prolonged FGF23- mediated hypophosphatemia as muscle weakness, bone pain, impaired mobility and fractures. Clinical diagnosis and management of TIO is challenging, but knowledge of this condition is still restricted to a few specialized centers, leading to delay of diagnosis and appropriate treatment. The scope of the present consensus is to provide an up-to-date guidance on the assessment and treatment of TIO.